Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein

See Ching Chan, Chung Mau Lo, Kelvin K.C. Ng, Irene O.L. Ng, Boon Hun Yong, Sheung Tat Fan – 28 January 2011 – The middle hepatic vein may be included in right liver living donor liver transplantation (LDLT) to optimize hepatic venous outflow. We studied the graft's ability to relieve portal hypertension and accommodate portal hyperperfusion with portal manometry and ultrasonic flowmetry. Surgical outcomes with respect to portal hemodynamometry were also investigated.

Portopulmonary hypertension as an indication for combined heart, lung, and liver or lung and liver transplantation: Literature review and case presentation

Nicole E. Scouras, Takashi Matsusaki, Charles D. Boucek, Cynthia Wells, Erik A. Cooper, Raymond M. Planinsic, Erin A. Sullivan, Christian A. Bermudez, Yoshiya Toyoda, Tetsuro Sakai – 28 January 2011 – End‐stage liver disease with severe portopulmonary hypertension (PPHTN), which is refractory to vasodilator therapies, is a contraindication for isolated liver transplantation (LT) because of the high mortality rate.

Fibrinogen‐γ proteolysis and solubility dynamics during apoptotic mouse liver injury: Heparin prevents and treats liver damage

Sujith V. W. Weerasinghe, David S. Moons, Peter J. Altshuler, Yatrik M. Shah, M. Bishr Omary – 27 January 2011 – Fas ligand (FasL)‐mediated hepatocyte apoptosis occurs in the context of acute liver injury that can be accompanied by intravascular coagulation (IC). We tested the hypothesis that analysis of selected protein fractions from livers undergoing apoptosis will shed light on mechanisms that are involved in liver injury that might be amenable to intervention.

Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma

Seung‐Oe Lim, Young Min Park, Hyeon Seop Kim, Xiaoyuan Quan, Jeong Eun Yoo, Young Nyun Park, Gi Hong Choi, Guhung Jung – 27 January 2011 – The tumor suppressor p53 is a key prognostic factor in hepatocellular carcinoma (HCC), yet only 35% of grade III tumors exhibit mutation of p53. Several other pathways have been implicated in HCC and, among these, the role of the Notch1/Snail pathway remains unclear. Therefore, we investigated the expression of p53, Notch1, and Snail proteins in HCC with regard to both clinical grade and p53 mutational status.

Subscribe to